Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A large-scale targeted proteomics assay resource based on an in vitro human proteome.
Matsumoto M, Matsuzaki F, Oshikawa K, Goshima N, Mori M, Kawamura Y, Ogawa K, Fukuda E, Nakatsumi H, Natsume T, Fukui K, Horimoto K, Nagashima T, Funayama R, Nakayama K, Nakayama KI. Matsumoto M, et al. Among authors: horimoto k. Nat Methods. 2017 Mar;14(3):251-258. doi: 10.1038/nmeth.4116. Epub 2016 Dec 26. Nat Methods. 2017. PMID: 28267743
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K. Kagamu H, et al. Among authors: horimoto k. Cancer Immunol Res. 2020 Mar;8(3):334-344. doi: 10.1158/2326-6066.CIR-19-0574. Epub 2019 Dec 23. Cancer Immunol Res. 2020. PMID: 31871122
IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada I, Hayashi Y, Fukui K, Horimoto K, Fukunaga K, Soejima K. Manabe T, et al. Among authors: horimoto k. Mol Cancer Res. 2020 Apr;18(4):549-559. doi: 10.1158/1541-7786.MCR-19-0956. Epub 2020 Jan 15. Mol Cancer Res. 2020. PMID: 31941753
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array.
Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Tomonari T, et al. Among authors: horimoto k. Oncotarget. 2020 Jun 30;11(26):2531-2542. doi: 10.18632/oncotarget.27640. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655838 Free PMC article.
162 results